![]() |
|
|
Vol. 289, Issue 3, 1410-1418, June 1999
Cardiac Diseases (A.W., C.F., M.W., G.O., W.S.,
T.J.C.), Chemical Sciences (M.M.A., S.A.A., J.A.B.), and Cardiovascular
Women's Health (J.H.S., N.W.N., D.W., T.M.A.), Wyeth-Ayerst Research,
Princeton, New Jersey
The effects of the ATP-dependent potassium channel agonists ZD6169,
celikalim, and WAY-133537 on bladder contractile function were examined
in vitro on isolated bladder strips and in vivo on spontaneous bladder
contractions. All three compounds produced a concentration-dependent
relaxation of isolated rat detrusor strips (IC50
values = 0.93, 0.03, and 0.09 µM, respectively for ZD6169,
celikalim, and WAY-133537. Contractile inhibition by all three
compounds was fully reversed by 6 µM glyburide. These compounds also
effectively inhibited spontaneous bladder contractions in the rat
hypertrophied bladder model of detrusor instability. We also examined
the electrophysiological properties of WAY-133537 on isolated rat
bladder detrusor myocytes. Myocytes had an average resting membrane
potential of
40 mV. Under patch current-clamp conditions, WAY-133537
(0.3 and 1.0 µM, n = 4-5) produced a significant hyperpolarization of 21 and 26 mV, respectively. Hyperpolarization was
reversed by the addition of 5 µM glyburide. In patch voltage-clamp studies, WAY-133537 (0.3 µM, n = 3) significantly
increased outward current in response to both voltage step and ramp
protocols consistent with activation of the ATP-dependent potassium
channel. In the detrusor instability model, WAY-133537 and celikalim
had similar oral potencies (ED50 = 0.13 and 0.3 mg/kg,
respectively), whereas ZD6169 was less potent (ED50 = 2.4 mg/kg). The antihypertensive agent celikalim exerted effects on the
bladder at doses that significantly reduced systemic blood pressure. In
contrast, both WAY-133537 and ZD6169 inhibited bladder hyperactivity at
doses that produced minimal changes in both mean arterial blood
pressure and heart rate. These data suggest that both WAY-133537 and
ZD6169 may be useful in the treatment of bladder instability at doses
associated with minimal hemodynamic side effects.
This article has been cited by other articles:
![]() |
S. Tertyshnikova, R. J. Knox, M. J. Plym, G. Thalody, C. Griffin, T. Neelands, D. G. Harden, L. Signor, D. Weaver, R. A. Myers, et al. BL-1249 [(5,6,7,8-Tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: A Putative Potassium Channel Opener with Bladder-Relaxant Properties J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 250 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-E. Andersson and A. J. Wein Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence Pharmacol. Rev., December 1, 2004; 56(4): 581 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gopalakrishnan, S. A. Buckner, K. L. Whiteaker, C.-C. Shieh, E. J. Molinari, I. Milicic, A. V. Daza, R. Davis-Taber, V. E. Scott, D. Sellers, et al. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. I. In Vitro Characterization J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 379 - 386. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Brune, T. A. Fey, J. D. Brioni, J. P. Sullivan, M. Williams, W. A. Carroll, M. J. Coghlan, and M. Gopalakrishnan (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. II. In Vivo Characterization J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 387 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Gopalakrishnan, S. A. Buckner, I. Milicic, D. R. Groebe, K. L. Whiteaker, D. J. Burns, U. Warrior, and M. Gopalakrishnan Functional Characterization of Adenosine Receptors and Coupling to ATP-Sensitive K+ Channels in Guinea Pig Urinary Bladder Smooth Muscle J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 910 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Christ, N. S. Day, M. Day, C. Santizo, W. Zhao, T. Sclafani, J. Zinman, K. Hsieh, K. Venkateswarlu, M. Valcic, et al. Bladder injection of "naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1699 - R1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. V. Petkov, T. J. Heppner, A. D. Bonev, G. M. Herrera, and M. T. Nelson Low levels of KATP channel activation decrease excitability and contractility of urinary bladder Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1427 - R1433. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Shieh, J. Feng, S. A. Buckner, J. D. Brioni, M. J. Coghlan, J. P. Sullivan, and M. Gopalakrishnan Functional Implication of Spare ATP-Sensitive K+ Channels in Bladder Smooth Muscle Cells J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 669 - 675. [Abstract] [Full Text] |
||||
![]() |
C.-C. Shieh, M. Coghlan, J. P. Sullivan, and M. Gopalakrishnan Potassium Channels: Molecular Defects, Diseases, and Therapeutic Opportunities Pharmacol. Rev., December 1, 2000; 52(4): 557 - 594. [Abstract] [Full Text] [PDF] |
||||